The effect of antidepressants and antipsychotics on weight gain in children and adolescents

Obesity Reviews

Volumn 16, Issue 7, 2015, Pages 566-580

  Reekie, J ^a   Hosking, S P M ^b   Prakash, C ^c,d   Kao, K T ^c,d   Juonala, M ^c,e,f   Sabin, M A ^c,d  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b PENINSULA HEALTH   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF TURKU   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adolescence; Antidepressant; Antipsychotic; Child; Obesity

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CLOZAPINE; LITHIUM; METFORMIN; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROATE SEMISODIUM;

ARTICLE; BODY WEIGHT; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT GAIN; ADOLESCENT; CHEMICALLY INDUCED; CHILD; DRUG ADMINISTRATION; DRUG EFFECTS; MENTAL DISORDERS; PEDIATRIC OBESITY; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MENTAL DISORDERS; PEDIATRIC OBESITY; RISK ASSESSMENT; RISK FACTORS; WEIGHT GAIN;

EID: 84931571104     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12284     Document Type: Article

References (91)

1. Bor W, Dean AJ, Najman J, Hayatbakhsh R. Are child and adolescent mental health problems increasing in the 21st century? A systematic review. Aust N Z J Psychiatry 2014; 48: 606-616.
2. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 2011; 72: 655-670.
3. Jane Costello E, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression? J Child Psychol Psychiatry 2006; 47: 1263-1271.
4. Cox GR, Callahan P, Churchill R etal. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. Cochrane Database Syst Rev 2014; (11): CD008324.
5. Maughan B, Collishaw S, Stringaris A. Depression in childhood and adolescence. J Can Acad Child Adolesc Psychiatry 2013; 22: 35-40.
6. DeFilippis M, Wagner KD. Management of treatment-resistant depression in children and adolescents. Paediatr Drugs 2014; 16: 353-361.
7. Smiga SM, Elliott GR. Psychopharmacology of depression in children and adolescents. Pediatr Clin North Am 2011; 58: 155-171. xi.
8. Voigt JP, Fink H. Serotonin controlling feeding and satiety. Behav Brain Res 2015; 277C: 14-31.
9. Galhardo J, Davis N, Matthai S, Shield JP. European Medicines Agency withdrawal for sibutramine. Arch Dis Child 2010; 95: 856.
10. Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs 2011; 71: 179-208.
11. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 1996; 274: 740-743.
12. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
13. Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs 2013; 15: 139-150.
14. Maiano C. Prevalence and risk factors of overweight and obesity among children and adolescents with intellectual disabilities. Obes Rev 2011; 12: 189-197.
15. Scott KM, Bruffaerts R, Simon GE etal. Obesity and mental disorders in the general population: results from the world mental health surveys. Int J Obes (Lond) 2008; 32: 192-200.
16. Dong C, Sanchez LE, Price RA. Relationship of obesity to depression: a family-based study. Int J Obes Relat Metab Disord 2004; 28: 790-795.
17. Anderson SE, Cohen P, Naumova EN, Jacques PF, Must A. Adolescent obesity and risk for subsequent major depressive disorder and anxiety disorder: prospective evidence. Psychosom Med 2007; 69: 740-747.
18. Richardson LP, Davis R, Poulton R etal. A longitudinal evaluation of adolescent depression and adult obesity. Arch Pediatr Adolesc Med 2003; 157: 739-745.
19. Goodman E, Must A. Depressive symptoms in severely obese compared with normal weight adolescents: results from a community-based longitudinal study. J Adolesc Health 2011; 49: 64-69.
20. Hryhorczuk C, Sharma S, Fulton SE. Metabolic disturbances connecting obesity and depression. Front Neurosci 2013; 7: 177.
21. Korczak DJ, Lipman E, Morrison K, Szatmari P. Are children and adolescents with psychiatric illness at risk for increased future body weight? A systematic review. Dev Med Child Neurol 2013; 55: 980-987.
22. Sabin MA, Shield JP. Childhood obesity. Front Horm Res 2008; 36: 85-96.
23. Tirosh A, Shai I, Afek A etal. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med 2011; 364: 1315-1325.
24. Juonala M, Magnussen CG, Berenson GS etal. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011; 365: 1876-1885.
25. Sabin MA, Ford AL, Holly JM, Hunt LP, Crowne EC, Shield JP. Characterisation of morbidity in a UK, hospital based, obesity clinic. Arch Dis Child 2006; 91: 126-130.
26. Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics 2007; 120: 340-345.
27. Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care 2005; 28: 902-909.
28. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 771-791.
29. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-1773.
30. Nilsson M, Joliat MJ, Miner CM, Brown EB, Heiligenstein JH. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14: 412-417.
31. Emslie GJ, Heiligenstein JH, Hoog SL etal. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43: 1397-1405.
32. Wagner KD, Ambrosini P, Rynn M etal. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290: 1033-1041.
33. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 721-729.
34. Rynn MA, Riddle MA, Yeung PP, Kunz NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007; 164: 290-300.
35. Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007; 46: 479-488.
36. Emslie GJ, Heiligenstein JH, Wagner KD etal. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205-1215.
37. Liebowitz MR, Turner SM, Piacentini J etal. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1431-1438.
38. Gherpelli JL, Esposito SB. A prospective randomized double blind placebo controlled crossover study of fluoxetine efficacy in the prophylaxis of chronic daily headache in children and adolescents. Arq Neuropsiquiatr 2005; 63: 559-563.
39. Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry 2007; 46: 1622-1632.
40. Rynn M, Wagner KD, Donnelly C etal. Long-term sertraline treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2006; 16: 103-116.
41. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001; 3: 22-27.
42. Jerrell JM. Neuroendocrine-related adverse events associated with antidepressant treatment in children and adolescents. CNS Neurosci Ther 2010; 16: 83-90.
43. Brent D, Emslie G, Clarke G etal. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299: 901-913.
44. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001; 11: 5-13.
45. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337-1346.
46. McCracken JT, McGough J, Shah B etal. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314-321.
47. Shea S, Turgay A, Carroll A etal. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: e634-e641.
48. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006; 163: 402-410.
49. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006; 21: 450-455.
50. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 2007; 46: 558-565.
51. Haas M, Delbello MP, Pandina G etal. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009; 11: 687-700.
52. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-weeks, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009; 19: 611-621.
53. Kent JM, Kushner S, Ning X etal. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord 2013; 43: 1773-1783.
54. Maayan LA, Vakhrusheva J. Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. Hum Psychopharmacol 2010; 25: 133-138.
55. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S, Risperidone Disruptive Behavior Study Group. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005; 44: 64-72.
56. Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002; 110: e34.
57. Troost PW, Lahuis BE, Steenhuis MP etal. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005; 44: 1137-1144.
58. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 2006; 16: 260-272.
59. Haas M, Eerdekens M, Kushner S etal. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009; 194: 158-164.
60. Findling RL, Robb A, Nyilas M etal. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165: 1432-1441.
61. Marcus RN, Owen R, Kamen L etal. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48: 1110-1119.
62. Owen R, Sikich L, Marcus RN etal. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124: 1533-1540.
63. Findling RL, Correll CU, Nyilas M etal. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-weeks, randomized, placebo-controlled study. Bipolar Disord 2013; 15: 138-149.
64. Hollander E, Wasserman S, Swanson EN etal. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16: 541-548.
65. Tohen M, Kryzhanovskaya L, Carlson G etal. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164: 1547-1556.
66. Kryzhanovskaya L, Schulz SC, McDougle C etal. Olanzapine versus placebo in adolescents with schizophrenia: a 6-weeks, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 60-70.
67. Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J. Comparison of open-label, 8-weeks trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009; 19: 539-545.
68. Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann N Y Acad Sci 2014; 1311: 1-13.
69. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163: 2072-2079.
70. Shaw P, Sporn A, Gogtay N etal. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63: 721-730.
71. Kumra S, Kranzler H, Gerbino-Rosen G etal. Clozapine and 'high-dose' olanzapine in refractory early-onset schizophrenia: a 12-weeks randomized and double-blind comparison. Biol Psychiatry 2008; 63: 524-529.
72. DelBello MP, Chang K, Welge JA etal. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009; 11: 483-493.
73. Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-weeks, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2012; 22: 327-342.
74. Schimmelmann BG, Mehler-Wex C, Lambert M etal. A prospective 12-weeks study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 2007; 17: 768-778.
75. Arango C, Robles O, Parellada M etal. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009; 18: 418-428.
76. Sikich L, Frazier JA, McClellan J etal. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165: 1420-1431.
77. Findling RL, Johnson JL, McClellan J etal. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010; 49: 583-594. quiz 632.
78. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-weeks trial. Neuropsychopharmacology 2004; 29: 133-145.
79. Miral S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008; 17: 1-8.
80. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004; 43: 206-214.
81. Geller B, Luby JL, Joshi P etal. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 2012; 69: 515-528.
82. Pavuluri MN, Henry DB, Findling RL etal. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord 2010; 12: 593-605.
83. Wake M, Campbell MW, Turner M etal. How training affects Australian paediatricians' management of obesity. Arch Dis Child 2013; 98: 3-8.
84. Ferguson JM, Feighner JP. Fluoxetine-induced weight loss in overweight non-depressed humans. Int J Obes 1987; 11(Suppl. 3): 163-170.
85. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54: 321-325.
86. Lam DD, Przydzial MJ, Ridley SH etal. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008; 149: 1323-1328.
87. Sumithran P, Prendergast LA, Delbridge E etal. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597-1604.
88. Farias MM, Cuevas AM, Rodriguez F. Set-point theory and obesity. Metab Syndr Relat Disord 2011; 9: 85-89.
89. Rezvanian H, Hashemipour M, Kelishadi R, Tavakoli N, Poursafa P. A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity. World J Pediatr 2010; 6: 317-322.
90. Li X, Johnson MS, Smith DL Jr etal. Effects of risperidone on energy balance in female C57BL/6J mice. Obesity 2013; 21: 1850-1857.
91. Stefanidis A, Verty AN, Allen AM, Owens NC, Cowley MA, Oldfield BJ. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity 2009; 17: 16-24.